Price Chart

Profile

Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2023 sales), followed by EMEA (32%), and the Asia-Pacific (16%).
URL https://www.qiagen.com
Investor Relations URL https://corporate.qiagen.com/investor-relations/overview
HQ State/Province N/A
Sector Health Care
Industry Life Sciences Tools & Services
Equity Style Small Cap/Blend
Next Earnings Release Feb. 06, 2025 (est.)
Last Earnings Release Nov. 06, 2024
Next Ex-Dividend Date N/A
Last Ex-Dividend Date Jan. 30, 2024

Profile

Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2023 sales), followed by EMEA (32%), and the Asia-Pacific (16%).
URL https://www.qiagen.com
Investor Relations URL https://corporate.qiagen.com/investor-relations/overview
HQ State/Province N/A
Sector Health Care
Industry Life Sciences Tools & Services
Equity Style Small Cap/Blend
Next Earnings Release Feb. 06, 2025 (est.)
Last Earnings Release Nov. 06, 2024
Next Ex-Dividend Date N/A
Last Ex-Dividend Date Jan. 30, 2024